Quarterly report pursuant to Section 13 or 15(d)

Collaboration, Financing, and License Agreements - Additional Information (Detail)

v3.21.2
Collaboration, Financing, and License Agreements - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Janssen Pharmaceutical NV [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Accrued royalties $ 0 $ 0 $ 0 $ 0
Janssen Pharmaceutical NV [Member] | Maximum [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Percentage of royalty on net sales     8.00%  
DiaTex, Inc. [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Royalty payment 0 0 $ 0 0
Development payment $ 0 $ 0 $ 0 $ 0